Physician profile
Daniel H Isaac
NPI 1508983354
$4,668.73
in general payments reported to CMS, 2019-2025
17 companies · $756 in 2025
The $756 reported for 2025 was more than what 81% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $201 · 2021: $376 · 2022: $528 · 2023: $741 · 2024: $1,481 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,977.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,086.31 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $921.09 | 2022-2025 | Infuse, Vyzulta, Lenscrafters |
| Alcon Vision LLC | $779.39 | 2019-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $467.02 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $279.17 | 2019-2024 | Contact Lens, Spectacle Lenses |
| Genzyme Corporation | $186.62 | 2022-2024 | |
| Coopervision INC. | $165.62 | 2019-2025 | Misight Contact Lens, Clariti Contact Lens, Paragon Crt |
| Sight Sciences, INC. | $148.27 | 2022-2024 | Tearcare System |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Dompe US, INC. | $117.44 | 2024 | Oxervate |
| Amgen INC. | $89.74 | 2024 | Tepezza |
| Sun Pharmaceutical Industries INC. | $84.38 | 2023 | Cequa |
| Apellis Pharmaceuticals, INC. | $79.97 | 2024 | Syfovre |
| Allergan, INC. | $78.15 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $32.20 | 2024-2025 | Xdemvy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.87 | 2023 | |
| Maculogix, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Isaac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.